NCT06094296

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

A Randomized, Double-blind, Phase 2 Study of BMS-986315 and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of BMS-986315 plus nivolumab in combination with platinum-based doublet chemotherapy (PDCT) versus nivolumab in combination with PDCT in the first-line treatment of Stage IV or recurrent non-small cell lung cancer (NSCLC).

Conditions

• NSCLC

Interventions

Type	Name	Description
DRUG	BMS-986315	Specified dose on specified days
DRUG	Nivolumab	Specified dose on specified days
DRUG	Pemetrexed	Specified dose on specified days
DRUG	Cisplatin	Specified dose on specified days
DRUG	Carboplatin	Specified dose on specified days
DRUG	Paclitaxel	Specified dose on specified days

Timeline

• Start date: 2023-11-27
• Primary completion: 2024-08-08
• Completion: 2024-08-08
• First posted: 2023-10-23
• Last updated: 2025-04-16
• Results posted: 2025-04-16

Locations

8 sites across 2 countries: United States, Australia

Regulatory

• FDA-regulated drug study